Last reviewed · How we verify
Trastuzumab plus Pertuzumab (trastuzumab-plus-pertuzumab)
Trastuzumab and pertuzumab target HER2, blocking signal transduction and preventing tumor growth.
At a glance
| Generic name | trastuzumab-plus-pertuzumab |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 2 |
Mechanism of action
Trastuzumab and pertuzumab work together to bind to different parts of the HER2 receptor, inhibiting the signals that promote cancer cell growth and survival. This dual inhibition can lead to a more effective reduction in tumor size and progression.
Approved indications
Common side effects
- Diarrhoea
- Alopecia
- Nausea
- DIARRHOEA
- NAUSEA
- ALOPECIA
- Fatigue
- FATIGUE
- Anaemia
- Neutropenia
- Vomiting
- Decreased appetite
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management (PHASE2)
- A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo®. (PHASE1)
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trastuzumab plus Pertuzumab CI brief — competitive landscape report
- Trastuzumab plus Pertuzumab updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI